Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 2/20 | 0.35 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.35 |
| ▸ | BAD | Q92934 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15614326 | 0.83 | APP (0.36) | MAPK14ALOX5ALDH1A1LMNABCL2L1 | |
| SCHEMBL17016670 | 0.80 | HPGD (0.44) | MAPK14ALOX5ADORA2AADORA2BADORA1 | |
| SCHEMBL16616411 | 0.78 | ALDH1A1 (0.44) | ADORA2AADORA2BADORA1ALDH1A1LMNA | |
| SCHEMBL17016709 | 0.77 | MAPK14 (0.39) | MAPK14ALOX5ALDH1A1TRPM8BCL2L1 | |
| SCHEMBL30738312 | 0.69 | KDM4E (0.41) | MAPK14ALOX5ADORA2AADORA2BADORA1 | |
| SCHEMBL22179699 | 0.69 | KDM4E (0.41) | MAPK14ALOX5ADORA2AADORA2BADORA1 | |
| SCHEMBL15577566 | 0.68 | PDGFRB (0.42) | MAPK14TP53 | |
| SCHEMBL12004268 | 0.68 | NQO2 (0.42) | ALDH1A1LMNANPC1RAB9AKDM4E | |
| SCHEMBL17016707 | 0.67 | MAP4K4 (0.44) | ALOX5EGLN1 | |
| SCHEMBL6590702 | 0.67 | EGLN1 (0.46) | MAPK14ALOX5ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932323-B2 | Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170204083-A1 | THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-07-20 | — | — | US | disclosed |
| US-9573938-B2 | Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-02-21 | — | — | US | disclosed |
| US-20150232454-A1 | THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204083-A1 | THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES | XDH, DPYD, P4HA1 | MAPK14 3982/4885ALOX5 2325/4885ADORA2A 447/4885 |
| US-20150232454-A1 | THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES | XDH, DPYD, DHX15 | MAPK14 4176/4885ALOX5 2463/4885ADORA2A 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.